Gen­er­a­tion Bio to lay off 68 em­ploy­ees in a dif­fi­cult year for non-vi­ral gene ther­a­py biotechs

Ge­net­ic med­i­cines mak­er Gen­er­a­tion Bio will lay off 68 work­ers, in­clud­ing two mem­bers of its ex­ec­u­tive team, and will shrink its R&D scope to ex­tend its run­way by 18 months, CEO Ge­off Mc­Do­nough told End­points News.

Wednes­day’s an­nounce­ment of the 40% work­force re­duc­tion serves as an­oth­er blow to the non-vi­ral gene ther­a­py field, which has seen pri­vate star­tups like Sum­ma­tion Bio and In­ter­galac­tic Ther­a­peu­tics shut­ter this year (there have al­so been a few fi­nanc­ings). Gen­er­a­tion Bio formed in 2016 with the aim of de­liv­er­ing the first non-vi­ral gene ther­a­py and had hoped to be in the clin­ic last year, but poor an­i­mal da­ta in 2021 set it back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER